Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$6.40

-0.39 (-5.74%)

18:07
10/09/16
10/09
18:07
10/09/16
18:07

Adaptimmune reports data on NY-ESO SPEAR T-cell receptor therapy

Adaptimmune Therapeutics announced a presentation of updated data on its lead clinical program, an NY-ESO SPEAR T-cell receptor therapy, in patients with synovial sarcoma at the European Society for Medical Oncology 2016 Congress. The study included Cohort 1: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 2: Subjects with low NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 3: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide alone -- no fludarabine; and Cohort 4: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with a modified lower dose than Cohort I of cyclophosphamide and fludarabine. In Cohort 1, the median duration of response is reported to be approximately 31 weeks as of the August 31 data cutoff. Ongoing NY-ESO SPEAR T-cell persistence has been observed for up to 36 months. In Cohort 2, four subjects of a targeted 10 are currently enrolled in the second cohort; three patients have been treated with NY-ESO SPEAR T-cells. As of August 31, best responses seen in these three patients were: one partial response, one stable disease, and one progressive disease. In Cohorts 3 and 4, five patients are currently enrolled in the third cohort; no objective responses have been observed to date. As pre-specified in the protocol, enrollment in cohort 3 has ceased, and company has initiated enrollment in Cohort 4. NY-ESO SPEAR T-cells continue to demonstrate a generally acceptable benefit:risk profile in all treated patients to date. Most common toxicities related to therapy can be monitored and managed with medical intervention and supportive care. While there are differences in the patient populations, incidence of cytokine release syndrome with NY-ESO-1c259 SPEAR T appears to be of lower frequency and severity than reported with CD19 CAR-T therapy. As previously reported at the 2016 Annual American Society of Clinical Oncology Meeting, there was one fatal SAE of bone marrow failure in Cohort 2 of the synovial sarcoma trial. Internal investigations have not identified a mechanism by which NY-ESO SPEAR T-cells may have caused bone marrow failure.

  • 09

    Oct

ADAP Adaptimmune
$6.40

-0.39 (-5.74%)

02/25/16
02/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at SunTrust by analyst Bruce Nudell, who expects an organic growth accelerating through 2018 driven by structural heart sales and core market stabilization. 2. Kite Pharma (KITE) initiated with a Buy, with analyst Robyn Karnauskas saying that Kite's technology could be the first to market and its data in the largest blood cancer market look similar to competition. The analyst also started Juno Therapeutics (JUNO) and Adaptimmune (ADAP) with Buy ratings. 3. Insulet (PODD) initiated with a Sell at Empire by analyst Cathy Reese, who said the company has several issues with its OmniPod System that will not be remedied with planned upgrades. 4. Biogen (BIIB) initiated with a Buy at Citi. 5. Crown Castle (CCI) initiated with a Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
LEER
08/04/16
NO CHANGE
LEER
Outperform
Adaptimmune partial clinical hold on planned trial 'surprising,' says Leerink
Leerink analyst Michael Schmidt sees the announced partial clinical hold on Adaptimmune's liposarcoma study as "surprising" and notes that it introduces some additional risk. However, the analyst says the news does not "fundamentally" change his investment thesis on Adaptimmune as he expects a rapid resolution. Schmidt reiterates an Outperform rating on the shares.
08/26/16
SBSH
08/26/16
NO CHANGE
SBSH
Buy
Adaptimmune partial clinical hold may be lifted within weeks, says Citi
Citi analyst Robyn Karnauskas said that after traveling with several members of Adaptimmune's management team, including its CEO and CFO, she came away feeling that their TCR platform remains in the lead despite delays. The FDA's partial clinical hold in myxoid round cell liposarcoma, or MRCLS, was not related to safety or efficacy of the product and Karnauskas sees the potential for the FDA to possibly reverse the partial clinical hold within a few weeks, she tells investors. Citi keeps a Buy rating on Adaptimmune shares.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.

TODAY'S FREE FLY STORIES

ANCUF

Alimentation Couche-Tard

$49.16

1.0803 (2.25%)

, CST

CST Brands

$48.53

-0.01 (-0.02%)

18:19
06/27/17
06/27
18:19
06/27/17
18:19
Hot Stocks
Alimentation Couche-Tard cleared in Canada for acquisition of CST Brands »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.16

1.0803 (2.25%)

CST

CST Brands

$48.53

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSLI

Merus Labs

$1.23

-0.0015 (-0.12%)

18:01
06/27/17
06/27
18:01
06/27/17
18:01
Hot Stocks
Merus Labs reminds shareholders to vote for arrangement with Norgine »

Merus Labs International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGI

Endurance

$8.20

-0.15 (-1.80%)

18:01
06/27/17
06/27
18:01
06/27/17
18:01
Hot Stocks
Endurance chief administration officer Andreasen to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$186.97

0.68 (0.37%)

17:41
06/27/17
06/27
17:41
06/27/17
17:41
Hot Stocks
Huntington Ingalls receives contract modifications to incorporate upgrades »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$56.18

-0.55 (-0.97%)

17:34
06/27/17
06/27
17:34
06/27/17
17:34
Hot Stocks
International Paper agrees to settle Kleen Products class action litigation »

International Paper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUSA

Houston American Energy

$0.67

0.0385 (6.10%)

17:33
06/27/17
06/27
17:33
06/27/17
17:33
Syndicate
Houston American Energy requests withdrawal of registration statement »

The company determined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.82

0.04 (0.18%)

, RYI

Ryerson

$9.00

-0.1 (-1.10%)

17:24
06/27/17
06/27
17:24
06/27/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: KB…

KBH

KB Home

$22.82

0.04 (0.18%)

RYI

Ryerson

$9.00

-0.1 (-1.10%)

AVAV

AeroVironment

$32.49

1.52 (4.91%)

CAMP

CalAmp

$19.25

-0.37 (-1.89%)

GMRE

Global Medical REIT

$9.83

0.07 (0.72%)

WLL

Whiting Petroleum

$5.48

0.04 (0.74%)

OAS

Oasis Petroleum

$7.93

0.21 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 03

    Jul

  • 04

    Jul

  • 05

    Jul

  • 28

    Jun

CHKE

Cherokee

17:22
06/27/17
06/27
17:22
06/27/17
17:22
Hot Stocks
Breaking Hot Stocks news story on Cherokee »

Cherokee says announcing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

KBH

KB Home

$22.82

0.04 (0.18%)

17:16
06/27/17
06/27
17:16
06/27/17
17:16
Hot Stocks
KB Home sees Q3 housing revenue $1.08B-$1.15B »

Sees Q3 average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

KBH

KB Home

$22.82

0.04 (0.18%)

17:16
06/27/17
06/27
17:16
06/27/17
17:16
Hot Stocks
KB Home raises FY17 housing revenue view to $4.2B-$4.4B from $4B-$4.3B »

Sees FY17 average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

17:15
06/27/17
06/27
17:15
06/27/17
17:15
General news
Breaking General news story  »

Minneapolis Federal…

CHKE

Cherokee

17:13
06/27/17
06/27
17:13
06/27/17
17:13
Hot Stocks
Cherokee receives listing notice over late 10-Q »

Cherokee announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

BEP

Brookfield Renewable

$33.03

0.1 (0.30%)

, BAM

Brookfield

$39.47

0.33 (0.84%)

17:13
06/27/17
06/27
17:13
06/27/17
17:13
Syndicate
Brookfield Renewable files to sell 8.3M L.P. units on bought deal basis »

Brookfield Renewable…

BEP

Brookfield Renewable

$33.03

0.1 (0.30%)

BAM

Brookfield

$39.47

0.33 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$121.59

-0.28 (-0.23%)

17:11
06/27/17
06/27
17:11
06/27/17
17:11
Hot Stocks
United Technologies responds to reports regarding Carrier manufacturing facility »

In response to recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPTN

SpartanNash

$25.30

0.22 (0.88%)

17:07
06/27/17
06/27
17:07
06/27/17
17:07
Hot Stocks
SpartanNash says CFO Meyers resigns »

SpartanNash disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARO

FARO Technologies

$36.10

-0.65 (-1.77%)

17:06
06/27/17
06/27
17:06
06/27/17
17:06
Initiation
FARO Technologies initiated  »

FARO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$14.98

-0.03 (-0.20%)

17:05
06/27/17
06/27
17:05
06/27/17
17:05
Hot Stocks
Monmouth Real Estate acquires South Carolina industrial building for $22M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

WDC

Western Digital

$91.85

-0.81 (-0.87%)

, TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

17:03
06/27/17
06/27
17:03
06/27/17
17:03
Hot Stocks
Western Digital announces new 3D NAND technology, touts strength in Japan JV »

Western Digital (WDC)…

WDC

Western Digital

$91.85

-0.81 (-0.87%)

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$49.98

-0.19 (-0.38%)

17:03
06/27/17
06/27
17:03
06/27/17
17:03
Hot Stocks
Fresh Del Monte and Del Monte Pacific announce series of joint ventures »

Del Monte Pacific and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.50

-0.28 (-0.57%)

, ALOG

Analogic

$68.15

-0.85 (-1.23%)

17:03
06/27/17
06/27
17:03
06/27/17
17:03
Hot Stocks
American Airlines, Analogic announce partnership to improve aviation security »

American Airlines (AAL)…

AAL

American Airlines

$48.50

-0.28 (-0.57%)

ALOG

Analogic

$68.15

-0.85 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

DOW

Dow Chemical

$63.09

-0.48 (-0.76%)

, DD

DuPont

$80.69

-0.47 (-0.58%)

16:59
06/27/17
06/27
16:59
06/27/17
16:59
Hot Stocks
Canada Competition Bureau reaches agreement with DuPont, Dow Chemical on merger »

Canada's Competition…

DOW

Dow Chemical

$63.09

-0.48 (-0.76%)

DD

DuPont

$80.69

-0.47 (-0.58%)

FMC

FMC Corporation

$74.01

-0.76 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

GMRE

Global Medical REIT

$9.83

0.07 (0.72%)

16:47
06/27/17
06/27
16:47
06/27/17
16:47
Hot Stocks
Global Medical REIT provides update on acquisition of cardiac clinic in Lubbok »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYI

Ryerson

$9.00

-0.1 (-1.10%)

16:46
06/27/17
06/27
16:46
06/27/17
16:46
Hot Stocks
Ryerson comments on Q2 market conditions, demand environment »

In a press release…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYI

Ryerson

$9.00

-0.1 (-1.10%)

16:43
06/27/17
06/27
16:43
06/27/17
16:43
Earnings
Ryerson sees Q2 net income $0M-$2M »

EPS consensus 35c. Says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:38
06/27/17
06/27
16:38
06/27/17
16:38
General news
API crude inventories for week of June 23 »

API reports that crude…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.